electroCore, Inc. ECOR
Set alert
At close · Oct 30
After hours · Oct 30, 7:43 PM ET
- YTD
- +67.48%
- 1 year
- +54.10%
- Open
- 7.76
- Prev close
- 8.11
- Mkt cap
- 67.80M
- Vol
- 65.78K
- Avg vol
- 87.68K
- EPS
- -1.65
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 7.50
- High
- 8.54
- Forward P/E
- -31.85
- Beta
- 0.56
- Short ratio
- 0.54
- Inst. own
- 16.11%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 7, 2024
- 50-d avg
- 11.57
- 200-d avg
- 7.64
- 1y target
- 25.47
News
3 days ago globenewswire.com
electroCore to Announce Third Quarter September 30, 2026, Financial Results on Wednesday, November 4, 2026
ROCKAWAY, N.J., Oct. 29, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that it will report its financial…
4 days ago marketbeat.com
electroCore Targets 2027 EBITDA Profit as VA, Quell and CIPN Opportunities Expand
Joshua Lev, co-CEO, president and CFO of electroCore NASDAQ: ECOR, said the commercial-stage bioelectronic health and wellness company is seeking to broaden its federal-market presence, expand…
-
4 days ago benzinga.com
electroCore Submits Premarket Notification Seeking Clearance From FDA For Its Quell Wearable Neuromodulation Platform To Treat Chronic Chemotherapy-Induced Peripheral Neuropathy
electroCore, Inc. (NASDAQ:ECOR), ("electroCore" or the "Company"), a bioelectronic technology company, today announced that it has submitted a 510(k) premarket notification to the U.S. Food and Drug
4 days ago globenewswire.com
electroCore, Inc. Submits 510(k) Premarket Notification to FDA Seeking Clearance of Quell® for the Treatment of Chronic Chemotherapy-Induced Peripheral Neuropathy (CIPN)
ROCKAWAY, N.J., Oct. 28, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), (“electroCore” or the “Company”), a bioelectronic technology company, today announced that it has submitted a…
4 days ago defenseworld.net
electroCore (NASDAQ:ECOR) Share Price Crosses Above 200-Day Moving Average – Here’s What Happened
electroCore, Inc. (NASDAQ: ECOR - Get Free Report)'s stock price passed above its 200-day moving average during trading on Tuesday. The stock has a 200-day moving average of $7.70 and traded as high…
5 days ago globenewswire.com
fMRI Study Suggests Transcutaneous Cervical Vagus Nerve Stimulation (tcVNS) Accelerates Neural Processes in Visual Skill Learning
ROCKAWAY, N.J.,, Oct. 27, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR) (“electroCore” or the “Company”), a commercial-stage bioelectronic medicine and wellness company, today announced…
1 week ago globenewswire.com
electroCore to Present at Planet MicroCap Toronto 2026 powered by MicroCapClub
ROCKAWAY, N.J., Oct. 21, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that it will be presenting at…
3 weeks ago defenseworld.net
electroCore (NASDAQ:ECOR) and Enovis (NYSE:ENOV) Head-To-Head Comparison
electroCore (NASDAQ: ECOR - Get Free Report) and Enovis (NYSE: ENOV - Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two…
1 month ago seekingalpha.com
electroCore Has A Line Of Sight At Cash Breakeven
electroCore is showing operational and financial improvement, driven by sales force expansion and strong Quell Fibromyalgia growth. ECOR targets >30% FY26 revenue growth, 85%+ gross margins, and…
1 month ago defenseworld.net
Thomas Errico Purchases 5,000 Shares of electroCore (NASDAQ:ECOR) Stock
electroCore, Inc. (NASDAQ: ECOR - Get Free Report) Director Thomas Errico bought 5,000 shares of the company's stock in a transaction dated Monday, September 14th. The stock was bought at an average…
1 month ago zacks.com
electroCore (ECOR) Stock Jumps 6.9%: Will It Continue to Soar?
electroCore (ECOR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
1 month ago benzinga.com
Full Transcript: electroCore Q2 2026 Earnings Call
electroCore (NASDAQ:ECOR) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. This content is powered by…
1 month ago globenewswire.com
electroCore to Participate at H.C. Wainwright Global Investment Conference
ROCKAWAY, N.J., Sept. 10, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that management will participate…
-
1 month ago benzinga.com
electroCore Appoints Joshua Lev, Mike Fox As Co-CEOs, Effective Sept. 8
electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine and wellness company and leader in non-invasive vagus nerve stimulation technologies, today announced that it has appointed…
1 month ago globenewswire.com
electroCore, Inc. Appoints Joshua Lev and Mike Fox as Co-Chief Executive Officers
ROCKAWAY, N.J., Sept. 09, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company and leader in non-invasive vagus nerve stimulation…
2 months ago globenewswire.com
electroCore's Truvaga® Named Best Luxury Biohacking & Longevity Brand in the USA by Luxury Lifestyle Awards
Recognition highlights Truvaga's combination of patented non-invasive vagus nerve stimulation technology, thoughtful design and personalized wellness experience Recognition highlights Truvaga's…
2 months ago seekingalpha.com
electroCore, Inc. (ECOR) Q2 2026 Earnings Call Transcript
electroCore, Inc. (ECOR) Q2 2026 Earnings Call Transcript
2 months ago marketbeat.com
electroCore Q2 Earnings Call Highlights
electroCore NASDAQ: ECOR reported second-quarter 2026 revenue of $9.5 million, up approximately 28% from $7.4 million a year earlier, as growth in Veterans Affairs prescription sales and…
2 months ago zacks.com
electroCore, Inc. (ECOR) Reports Q2 Loss, Tops Revenue Estimates
electroCore, Inc. (ECOR) came out with a quarterly loss of $0.33 per share versus the Zacks Consensus Estimate of a loss of $0.41. This compares to a loss of $0.35 per share a year ago.
-
2 months ago benzinga.com
electroCore Lowers FY2026 Sales Guidance from $41.642M to $41.600M vs $41.921M Est
electroCore (NASDAQ:ECOR) lowers FY2026 sales outlook from $41.642 million to $41.600 million vs $41.921 million estimate.
-
2 months ago benzinga.com
electroCore Q2 EPS $(0.33) Beats $(0.40) Estimate, Sales $9.450M Miss $9.491M Estimate
electroCore (NASDAQ:ECOR) reported quarterly losses of $(0.33) per share which beat the analyst consensus estimate of $(0.40) by 17.5 percent. This is a 25 percent increase over losses of $(0.44) per…
2 months ago globenewswire.com
electroCore Announces Second Quarter 2026 Financial Results
Second quarter 2026 net sales of $9.5 million, an increase of 28% over $7.4 million in the second quarter 2025 Net loss of $3.1 million decreased 17% from prior year with Adjusted EBITDA net loss…
3 months ago globenewswire.com
electroCore to Participate in Upcoming Investor Conferences
ROCKAWAY, N.J., Aug. 03, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that management will participate in…
3 months ago globenewswire.com
electroCore to Announce Second Quarter June 30, 2026, Financial Results on Thursday, August 6, 2026
ROCKAWAY, N.J., July 30, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that it will report financial…
3 months ago proactiveinvestors.co.uk
Ecora Royalties reports 61% jump in strong quarter
Ecora Royalties PLC (LSE:ECOR, TSX:ECOR, OTCQX:ECRAF, FRA:HGR) reported that its quarterly portfolio contribution jumped 61% year-on-year to US$19 million, driven by record cobalt receipts from the…
-
3 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Catheter Precision (AMEX:VTAK) shares moved upwards by 95.7% to $1.4 during Wednesday's regular session. The market value of their outstanding shares is at $2.5 million. Tvardi Therapeutics…
-
4 months ago benzinga.com
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers Gain Therapeutics (NASDAQ:GANX) stock rose 20.2% to $2.38 during Monday's after-market session. The market value of their outstanding shares is at $74.6 million. BNB Plus (NASDAQ:BNBX) stock…
-
5 months ago benzinga.com
electroCore Announces Publication Of New Clinical Findings For Quell Device, A Wearable Stimulation Device For The Treatment Of Fibromyalgia
The publication in JAMA Network Open, titled, "Transcutaneous Electrical Nerve Stimulation and Pain With Movement in People With Fibromyalgia: A Cluster Randomized Clinical Trial."The study evaluated…
-
5 months ago benzinga.com
electroCore Affirms FY2026 Sales Guidance of $41.642M vs $41.957M Est
electroCore (NASDAQ:ECOR) affirms FY2026 sales outlook from $41.642 million to $41.642 million vs $41.957 million estimate.
-
5 months ago benzinga.com
electroCore Q1 EPS $(0.59) Misses $(0.51) Estimate, Sales $9.584M Beat $9.012M Estimate
electroCore (NASDAQ:ECOR) reported quarterly losses of $(0.59) per share which missed the analyst consensus estimate of $(0.51) by 15.69 percent. This is a 25.53 percent decrease over losses of…
-
7 months ago benzinga.com
electroCore Announces New Clinical Findings Published That Demonstrates Potential Benefits Of Adjunctive Non-invasive Vagus Nerve Stimulation In Patients With Chronic Mild Traumatic Brain Injury And Comorbid Post-traumatic Stress Disorder
The publication reports results from a post-hoc analysis of 35 patients with chronic mTBI and PTSD. The analysis showed that adjunctive nVNS significantly reduced overall symptom burden, with…
-
7 months ago benzinga.com
electroCore Announces Issuance Of Two New Additions To U.S. Patent Portfolio
U.S. Patent No. 12,208,263, entitled "Devices and Methods for Vagal Nerve Stimulation" was issued on January 28, 2026U.S. Patent No. 12,213,795, entitled "Devices and Methods for Remote Therapy and…
-
7 months ago benzinga.com
Earnings Scheduled For March 26, 2026
Earnings Scheduled For March 26, 2026
-
7 months ago benzinga.com
electroCore Q4 EPS $(0.34) Beats $(0.41) Estimate, Sales $9.200M Beat $9.039M Estimate
electroCore (NASDAQ:ECOR) reported quarterly losses of $(0.34) per share which beat the analyst consensus estimate of $(0.41) by 16.46 percent. This is a 15 percent increase over losses of $(0.40)…
-
7 months ago benzinga.com
ElectroCore CEO Dan Goldberger To Retire On April 1; Joshua Lev Appointed Interim President, CFO; Michael Fox Appointed COO
electroCore, Inc. (Nasdaq: ECOR) ("electroCore" or the "Company"), a bioelectronic technology company, today announced full year 2025 financial results.Announced Chief Executive Officer, Dan…
-
7 months ago benzinga.com
Earnings Scheduled For March 19, 2026
Earnings Scheduled For March 19, 2026
-
9 months ago benzinga.com
HC Wainwright & Co. Maintains Buy on electroCore, Lowers Price Target to $18
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains electroCore (NASDAQ:ECOR) with a Buy and lowers the price target from $25 to $18.
-
9 months ago benzinga.com
electroCore Announces Acacia Clinics And The Vagus Nerve Society Launch New Research Initiative To Mull Gammacore Sapphire Use As Treatment For Symptoms Associated With PTSD
electroCore, Inc. (Nasdaq: ECOR) ("electroCore" or the "Company"), a bioelectronic technology company, today announced that Acacia Clinics and the Vagus Nerve Society have launched a new research…
-
9 months ago benzinga.com
electroCore Anticipates Reporting FY25 Revenue Of ~$31.8M-$32M; Estimates Q4 Revenue To Be ~$9M-$9.2M
Record revenue of approximately $31.8 - $32.0 million for full-year 2025 and approximately $9.0 - $9.2 million for the three months ended December 31, 2025 Revenue growth of approximately 26% over…
-
11 months ago benzinga.com
ElectroCore Granted Patent # US 12469610 B2 For "SYSTEMS AND METHODS FOR TREATING BLOOD CLOTS WITH NERVE STIMULATION"
https://ppubs.uspto.gov/api/pdf/downloadPdf/12469610?requestToken=eyJzdWIiOiIzZTQ5MWI5NS0wZjI4LTQwYjQtOGIyNS05ZmVhNTU3MDU1MjYiLCJ2ZXIiOiJmYWMyMzBiNS1kYjU1LTQwZjMtYTA3Yi1lZTY3MjNlY2U5ZDAiLCJleHAiOjB9
-
12 months ago benzinga.com
electroCore Q3 EPS $(0.40), Inline, Sales $8.700M Beat $7.843M Estimate
electroCore (NASDAQ:ECOR) reported quarterly losses of $(0.40) per share which met the analyst consensus estimate. This is a 29.03 percent decrease over losses of $(0.31) per share from the same…
12 months ago benzinga.com
Earnings Scheduled For November 5, 2025
Earnings Scheduled For November 5, 2025
-
1 year ago benzinga.com
electroCore Announces Its GammaCore Sapphire Non-Invasive Vagus Nerve Stimulation Device Has Been Included In Long-Term Reimbursement Policy By Belgium's National Institute For Health And Disability Insurance
electroCore, Inc. (NASDAQ: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that gammaCore™ Sapphire (nVNS) has been included in a long-term reimbursement policy…
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Thursday's Intraday Session
12 Health Care Stocks Moving In Thursday's Intraday Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Wednesday's After-Market Session
12 Health Care Stocks Moving In Wednesday's After-Market Session
-
1 year ago benzinga.com
electroCore Q2 EPS $(0.44) Misses $(0.31) Estimate, Sales $7.381M Beat $7.219M Estimate
electroCore (NASDAQ:ECOR) reported quarterly losses of $(0.44) per share which missed the analyst consensus estimate of $(0.31) by 43.32 percent. This is a 15.79 percent decrease over losses of…
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Thursday's After-Market Session
12 Health Care Stocks Moving In Thursday's After-Market Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Thursday's Pre-Market Session
12 Health Care Stocks Moving In Thursday's Pre-Market Session